Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 35,419 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: alone Clear all
Active, not recruiting Not applicable Interventional

Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants

NCT04701437
View directory record Official record
Conditions
Hepatitis C
Interventions
Peer mentor, Standard of care
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 13, 2026, 2:32 PM EST
Terminated Not applicable Interventional Results available

Effect of Raised CBF During CEA on Cognition in DM Patients

NCT00597545
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Artery Stenosis, Diabetes, Cognitive Dysfunction
Interventions
Carotid endarterectomy, Shunt
Procedure · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Nov 13, 2026, 2:32 PM EST
Recruiting Not applicable Interventional

Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma

NCT07506239
View directory record Official record
Conditions
Low-grade Glioma, Recurrent Low Grade Glioma, Low Grade Glioma of Brain, Pediatric Cancer
Interventions
Laser Interstitial Thermal Therapy (LITT), Magnetic resonance imaging (MRI), Questionnaires
Device · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 13, 2026, 2:32 PM EST
Recruiting Phase 1 Interventional

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

NCT05954312
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
VVD-130037, Docetaxel, Paclitaxel, Pembrolizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
8
States / cities
Jacksonville, Florida • Sarasota, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 13, 2026, 2:32 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

NCT01036581
View directory record Official record
Conditions
Drug Abuse, Nicotine Dependence
Interventions
MagPro X100 Magnetic Stimulator, Transcranial Rotating Magnetic Stimulator, Magnetom Prisma Fit 3T Scanner
Device
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 13, 2026, 2:32 PM EST
Terminated Phase 1 Interventional Results available

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

NCT02468557
View directory record Official record
Conditions
Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Interventions
Idelalisib, Nab-paclitaxel, mFOLFOX6
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Isavuconazole and Digoxin

NCT01582412
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Digoxin, Healthy Volunteers
Interventions
Isavuconazole, digoxin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Emraclidine, Itraconazole, Carbamazepine, Metformin
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Nov 13, 2026, 2:32 PM EST
Not listed Not applicable Interventional

REvision of VSG with Ablation of the Mucosa Procedure

NCT06671119
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism
Interventions
Gastric Mucosal Ablation (GMA)
Device
Lead sponsor
Dr. Christopher McGowan
Other
Eligibility
22 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Nov 13, 2026, 2:32 PM EST
Completed Not applicable Interventional Results available

Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression

NCT00621751
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 1Phase 2 Interventional Results available

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

NCT01512251
View directory record Official record
Conditions
BRAF Mutant Metastatic Melanoma
Interventions
BKM120 Combined with Vemurafenib (PLX4032)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Nov 13, 2026, 2:32 PM EST
Withdrawn Phase 2 Interventional

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT04054245
View directory record Official record
Conditions
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
Interventions
LOXL2 Inhibitor PAT-1251, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Nov 13, 2026, 2:32 PM EST
Terminated Phase 2 Interventional Results available

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

NCT01225172
View directory record Official record
Conditions
Breast Cancer
Interventions
BMS-754807, letrozole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Nov 13, 2026, 2:32 PM EST
Not listed Phase 3 Interventional

Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant

NCT00174577
View directory record Official record
Conditions
Major Depression
Interventions
Risperidone
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Atlanta, Georgia • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Preoperative CHG Cloth on Healthy Subjects

NCT02291601
View directory record Official record
Conditions
Surgery
Interventions
Chlorhexidine Gluconate, Vehicle, DynaHex-2
Drug · Other
Lead sponsor
Medline Industries
Industry
Eligibility
16 Years and older
Enrollment
879 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Nov 13, 2026, 2:32 PM EST
Active, not recruiting Phase 3 Interventional Results available

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

NCT05678322
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 1Phase 2 Interventional Results available

Adoptive Transfer of Haplo-identical DLI for AML and MDS

NCT02046122
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Idarubicin, Cytarabine, DLI
Drug · Biological
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Nov 13, 2026, 2:32 PM EST
Terminated Phase 2 Interventional Results available

Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

NCT00832637
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer
Interventions
Cisplatin, Erlotinib, Gemcitabine
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
San Francisco, California • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy

NCT01332253
View directory record Official record
Conditions
Tonsillectomy
Interventions
Intravenous ibuprofen, Normal Saline
Drug · Other
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Louisville, Kentucky • Newark, New Jersey • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions

NCT01372345
View directory record Official record
Conditions
Fasting
Interventions
CIPRO®XR
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited, India
Industry
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

NCT03815695
View directory record Official record
Conditions
Healthy Volunteers, Sickle Cell Disease
Interventions
FT-4202/Placebo
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Long Beach, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Bunionectomy HTX-011 Administration Study

NCT03718039
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Luer Lock applicator, Vial access device, aprepitant
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 13, 2026, 2:32 PM EST
Terminated Phase 2 Interventional Results available

Tofacitinib For Treatment Of Chronic Pouchitis

NCT04580277
View directory record Official record
Conditions
Pouchitis, Ileal Pouchitis, Ileal Pouch
Interventions
Tofacitinib 10 mg
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Nov 13, 2026, 2:32 PM EST
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT02851277
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal, Placebo Intramuscular
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Nov 13, 2026, 2:32 PM EST